A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial

- Lamb, David S., Denham, James W., D'Este, Catherine, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, Delahunt, Brett

Picking the optimal duration of hormonal therapy in men with high-risk and locally advanced prostate cancer treated with radiotherapy

- Denham, James W., Steigler, Allison

Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term

- Wilcox, Chantelle, Kautto, Allison, Steigler, Allison, Denham, James W.

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Wynne, Chris, D'Este, Catherine, Lamb, David S., Joseph, David, Turner, Sandra, Matthews, John, Atkinson, Chris, North, John, Christie, David, Spry, Nigel A.

Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials

- D'Amico, Anthony V., Chen, Ming-Hui, de Castro, Mario, Loffredo, Marian, Lamb, David S., Steigler, Allison, Kantoff, Philip W., Denham, James W.

Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial

- Capp, Anne, Inostroza-Ponta, Mario, Atkinson, Chris, North, John, Poulsen, Michael, Spry, Nigel A., Tai, Keen-Hun, Wynne, Chris, Duchesne, Gillian, Steigler, Allison, Denham, James W., Bill, Dana, Moscato, Pablo, Lai, Chi, Christie, David, Lamb, David, Turner, Sandra, Joseph, David, Matthews, John

A methodology for the analysis of PSA response signatures

- Ebert, Martin A., Lamb, David S., Joseph, David J., Steigler, Allison, Denham, James W.

Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial

- Denham, James W., Steigler, Allison, Gleeson, Paul S., Greer, Peter B., D'Este, Catherine, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation

- Sharpley, Christopher F., Bitsika, Vicki, Christie, David R. H., Bradford, Rosemary, Steigler, Allison, Denham, James W.

PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer?

- Denham, James W., Lamb, David S., Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Duchesne, Gillian, Ebert, Martin, Steigler, Allison, D'Este, Catherine

Radiation dose escalation or longer androgen suppression for locally advanced prostate cancer? Data from the TROG 03.04 RADAR trial

- Denham, James W., Steigler, Allison, Tai, Keen-Hun, Gogna, Nirdosh Kumar, Gill, Suki, Tan, Hendrick, Kearvell, Rachel, Murray, Judy, Ebert, Martin, Haworth, Annette, Kennedy, Angel, Delahunt, Brett, Joseph, David, Oldmeadow, Christopher, Holliday, Elizabeth G., Attia, John, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Atkinson, Chris, Matthews, John, Turner, Sandra, Kenny, Lizbeth

Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer

- Denham, James W., Kumar, Mahesh, Turner, Sandra, Greer, Peter B., D'Este, Catherine, Steigler, Allison, Gleeson, Paul S., Lamb, David S., Joseph, David, Atkinson, Chris, Matthews, John, Tai, Keen-Hun, Spry, Nigel A., Christie, David

Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?

- Denham, James W., Steigler, Allison, Wilcox, Chantelle, Lamb, David S., Joseph, David, Atkinson, Chris, Tai, Keen-Hun, Spry, Nigel A., Gleeson, Paul S., D'Este, Catherine

Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking?

- Denham, James W., Steigler, Allison, Gleeson, Paul S., D'Este, Catherine, Kumar, Mahesh, Lamb, David S., Joseph, David, Spry, Nigel A., Tai, Keen-Hun, Atkinson, Chris, Turner, Sandra, Greer, Peter B.

Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer

- D'Amico, Anthony V., Chen, Ming-Hui, Crook, Juanita, Armstrong, John G., Malone, Shawn, Steigler, Allison, Dunne, Mary, Kantoff, Phillip W., Denham, James W.

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

- Denham, James W., Joseph, David, Lamb, David S., Spry, Nigel A., Duchesne, Gillian, Matthews, John, Atkinson, Chris, Tai, Keen-Hun, Christie, David, Kenny, Lizbeth, Turner, Sandra, Gogna, Nirdosh Kumar, Diamond, Terry, Delahunt, Brett, Oldmeadow, Chris, Attia, John, Steigler, Allison

Risk stratification after biochemical failure following curative treatment of locally advanced prostate cancer: data from the TROG 96.01 trial

- Steigler, Allison, Denham, James W., Tai, Keen-Hun, Wynne, Chris, Lamb, David S., Spry, Nigel A., Joseph, David, Matthews, John, Atkinson, Chris, Turner, Sandra, North, John, Christie, David

A randomised trial investigating the effect on biochemical (PSA) control and survival of different durations of adjuvant androgen deprivation in association with definitive radiation treatment for localised carcinoma of the prostate

- Lamb, David, Joesph, David, Turner, Sandra, Diamond, Terry, Steigler, Allison, Attia, John, Delahunt, Brett, Haworth, Annette, Denham, Jim, Duchesne, Gillian, Atkinson, Chris, Kenny, Lizbeth, Gogna, Kumar, Matthews, John, Spry, Nigel, Tai, Keen-Hun

Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer

- Denham, James W., Steigler, Allison, Wynne, Chris, Lamb, David S., Tai, Keen-Hun, Joseph, David, Matthews, John, Atkinson, Chris, Spry, Nigel A., Turner, Sandra, North, John, Christie, David

External validation of a predictive model of urethral strictures for prostate patients treated with HDR Brachytherapy boost

- Panettieri, Vanessa, Rancati, Tiiziana, Onjukka, Eva, Ebert, Martin A., Joseph, David J., Denham, James W., Steigler, Allison, Millar, Jeremy L.